Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. 1990

W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030.

The cystic fibrosis gene was recently cloned, and a three-base deletion removing phenylalanine 508 from the coding region was identified as the mutation on the majority of cystic fibrosis chromosomes. We used the polymerase chain reaction and hybridization with allele-specific oligonucleotides to analyze the presence or absence of this mutation on 439 cystic fibrosis chromosomes and 433 normal chromosomes from non-Ashkenazic white families. This mutation was present on 75.8 percent of the cystic fibrosis chromosomes. Using the DNA markers XV-2c and KM-19, we found that 96 percent of cystic fibrosis chromosomes with the mutation had a single DNA haplotype that occurs frequently with cystic fibrosis chromosomes. This haplotype was also found on 54 percent of the cystic fibrosis chromosomes without the three-base deletion. The three-base deletion was found on only 30.3 percent of cystic fibrosis chromosomes from Ashkenazic families, although the common cystic fibrosis haplotype was present on 97 percent of cystic fibrosis chromosomes from Ashkenazic families. The ability to detect the common mutation causing cystic fibrosis represents a major improvement in prenatal diagnosis and heterozygote detection, particularly in families in which no DNA sample is available from the affected child, and provides an improved method of testing for spouses of carriers of cystic fibrosis. Mutation analysis introduces the possibility of population-based screening programs for carriers, which on the basis of the sample in this study, would currently identify about 57 percent of the non-Ashkenazic white couples at risk.

UI MeSH Term Description Entries
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011296 Prenatal Diagnosis Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth. Diagnosis, Prenatal,Fetal Diagnosis,Fetal Imaging,Fetal Screening,Intrauterine Diagnosis,Antenatal Diagnosis,Antenatal Screening,Diagnosis, Antenatal,Diagnosis, Intrauterine,Prenatal Screening,Antenatal Diagnoses,Antenatal Screenings,Diagnosis, Fetal,Fetal Diagnoses,Fetal Imagings,Fetal Screenings,Imaging, Fetal,Intrauterine Diagnoses,Prenatal Diagnoses,Prenatal Screenings,Screening, Antenatal,Screening, Fetal,Screening, Prenatal
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D005315 Fetal Diseases Pathophysiological conditions of the FETUS in the UTERUS. Some fetal diseases may be treated with FETAL THERAPIES. Embryopathies,Disease, Fetal,Diseases, Fetal,Embryopathy,Fetal Disease
D006239 Haplotypes The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX. Haplotype
D006580 Genetic Carrier Screening Identification of individuals who are heterozygous at a GENETIC LOCUS for a recessive PHENOTYPE. Carriers, Genetic, Detection,Genetic Carriers, Detection,Heterozygote Detection,Carrier Detection, Genetic,Detection, Genetic Carrier,Genetic Carrier Detection,Heterozygote Screening,Carrier Screening, Genetic,Detection, Heterozygote,Screening, Genetic Carrier,Screening, Heterozygote,Screenings, Genetic Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
April 1982, Kinderarztliche Praxis,
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
January 1982, Annals of clinical and laboratory science,
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
July 1978, Science (New York, N.Y.),
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
October 1989, Lancet (London, England),
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
July 1992, Prenatal diagnosis,
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
August 1989, The Medical journal of Australia,
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
March 1989, Medicina clinica,
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
December 2000, European journal of pediatrics,
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
February 1993, Prenatal diagnosis,
W K Lemna, and G L Feldman, and B Kerem, and S D Fernbach, and E P Zevkovich, and W E O'Brien, and J R Riordan, and F S Collins, and L C Tsui, and A L Beaudet
January 2011, Journal of medical screening,
Copied contents to your clipboard!